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CIS- AND TRANS-ACTIVATION OF HORMONE RECEPTORS: 
THE LH RECEPTOR 
 
 
The Luteinizing hormone receptor (LHR) belongs to the G protein-coupled receptor family, as 
do the other glycoprotein hormone receptors for FSH, TSH, and CG. The LHR comprises two 
halves of ~350 amino acids: an extracellular hormone binding exodomain and a seven 
transmembrane-spanning endodomain responsible for signal generation. Hormone binds to the 
exodomain with high affinity, and the resulting conformational changes in the 
hormone/exodomain complex modulate the endodomain to generate hormone signals. Hormone 
binding to an LHR produces hormonal signals (cis-activation), but it is not known whether a 
liganded LHR could activate other unoccupied LHRs (trans-activation). The LHR activates both 
adenylyl cyclase and phospholipase Cβ. This dissertation shows that trans-activation of the LHR 
leads to the activation of adenylyl cyclase to induce cAMP but not to the activation of 
phospholipase Cβ to induce the inositol phosphate signaling. Trans-activation offers a 
mechanism of signal amplification at the receptor level and also provides a mechanism of 
multiple signal generation for a liganded LHR to cis-activate phospholipase Cβ and trans-
activate adenylyl cyclase. Also coexpression of Gi2 with a constitutively activating LHR 
(Asp578Gly), the most common mutation of male-limited precocious puberty, shows that Gi2 
could completely inhibit cAMP induction by the LHR mutant. Experiments using the carboxyl 
terminal region of G protein α subunits demonstrate that LHR has overlapping binding sites for 
Gα subunits Gs and Gi2. 
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Chapter 1     Introduction 
 
Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) 
 
LH, FSH, TSH, and CG belong to the glycoprotein hormone family (1). These hormones are 
heterodimers of α and β subunits; sharing a common α subunit consisting of 92 amino acids (1). 
Hormone-specific β subunits vary in size; 121 amino acids are found in the LHβ while hCGβ has 
145 amino acids (1) (Figure 1.1). LH, FSH, and TSH are released from the anterior pituitary, and 
CG originates from the placenta during pregnancy (1). LH and CG bind to the same receptor on 
granulosa cells, known as the LH/CG receptor or the LHR (2). 
 
FSH elicits the primary signal for starting preovulatory follicular development (3). It takes 10-12 
days of sustained stimulation by FSH for a ~5 mm follicle to attain a full preovulatory diameter 
of  ≥ 20 mm; during this time the number of its granulosa cells increases 5 or 6 fold to reach over 
50 million (4), while the number of FSHRs in each granulosa cell increases 4 to 5 fold (5). FSH 
directly stimulates proliferation of granulosa cells and induces the LH-responsive mechanisms in 
cells that will sustain steroid secretion by the preovulatory follicle and, after ovulation, the 
corpus luteum (3). FSH binds to the FSHR in granulosa cells, inducing mRNA expression of 
FSH-responsive genes such as LHR, steroidogenic enzyme P450 aromatase, and regulatory 
peptides such as inhibin subunits and follistatin (6).  
 
LH mediates the secretion of steroid hormones by the preovulatory follicles and corpus luteum 
(3). Estrogen secretion by the follicles increases during the second half of the follicular phase 
when the frequency of pulsatile LH discharge by the pituitary increases and FSH secretion 
decreases (3). During this stage of development, granulosa cells express LHR, and tonic levels of 
LH are able to directly stimulate steroidogenic enzyme systems preinduced by FSH (3). LH acts 
through the LHR on theca cells and mature granulosa cells to induce mRNA expression of LH-
responsive genes such as those responsible for precursor-cholesterol uptake and sustains high 
steroidogenic enzyme activity (6). An ovulation-inducing dose of LH is released by the pituitary 
gland at mid-menstrual cycle. This terminates proliferation of granulosa cells and simultaneously 
initiates rupture of the ovulatory follicle and onset of luteal progesterone secretion. If pregnancy 
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occurs, the functional lifespan of the corpus luteum is extended by choriogonadotropin acting 
through the same LH/CG receptor (3).  
 
The LH Receptor 
 
These cellular responses of LH, FSH, and CG are mediated by their cognate receptor on the cell 
surface. The LHR and the FSHR belong to the G protein-coupled receptor family, the largest 
known receptor family in the human genome (7). These receptors consist of two halves of ~350 
amino acids: the N-terminal half (exodomain) and the membrane-associated C-terminal half 
(endodomain) (7) (Figure 1.2). The exodomain consists of 10 exons and is mainly responsible for 
hormone binding (8, 9). The 11th exon encodes the endodomain which generates hormone 
signals (8, 9). The endodomain is equivalent in size to most of the other GPCRs which do not 
carry a long exodomain (7). The endodomain comprises seven transmembrane (TM) helices, 
three extracellular connecting loops (exoloops), three intracellular connecting loops (cytoloops), 
and a C-terminal tail (7).  
 
The LHRs are expressed in the Leydig cells in males, and in the theca cells and the mature 
granulosa cells in females. The expression of LHRs in the later developmental stage of the 
granulosa cells requires the continual presence of FSH (10, 11), and this induction of LHR by 
FSH is mediated by cAMP (12, 13).  
 
A study of hCG binding to ovarian receptors showed the Hill coefficient of 0.9 for LH and 1.1 
for hCG, suggesting binding of 1 mol of gonadotropin/mol of receptor (14). The number of 
LHRs expressed in Leydig cells or in ovarian granulosa cells are in the range of 6,000 – 20,000 
receptor/cell (15-17). However, studies suggest that only 1-3% of receptor occupancy is enough 
to induce maximal steroidogenesis in Leydig cells and granulosa cells (15, 18), suggesting the 
most likely function of excess receptors is to take up and clean circulating gonadotropins.  
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Hormone Binding and Receptor Activation 
 
Exodomain of the LHR binds to hCG with high affinity (9, 19). Many groups have revealed 
important regions on the LHR for hormone binding. It is now known that there are three 
important regions in the exodomain of the LHR for hormone binding: the N-terminal cysteine-
rich region, the LRR region, and the C-terminal cysteine-rich area (the hinge region) (Figure 1.3). 
A study using synthetic peptides identified four hormone binding regions of the LHR: Arg21-
Pro38 (near the N-terminus), Arg102-Thr115 (LRR 4), Tyr253-Phe272 (hinge region), and Lys573-
Lys583 (exoloop 3) (20). Further study on the N-terminal region of the LHR shows that crucial 
amino acids in the region for hormone binding are Leu20, Cys22, and Gly24 (21). It was also 
demonstrated that both the α and β subunits of hCG contact the N-terminal region of the LHR 
(22).  
 
The Leu-rich repeat (LRR) region, crucial for hormone binding, is located  in the center of the 
exodomain and has nine repeats, each of which are 20-28 amino acids long. Based on the crystal 
structure of LRR proteins (23), up to 15 LRRs form a non globular horseshoe-shaped structure 
with an inner lining of curved β strands and an outer lining of helices (24). The LRR 1-6 of the 
LHR were shown to be important for hormone binding (25), and our group further identified that 
the upstream LRR 2 and 4 and downstream LRR 7 and 8 were shown also important for 
hormone binding (26, 27). Affinity labeling study of the LRR 4 of the LHR showed that the N-
terminal region of LRR 4 interacts with hCG, preferentially the hCG α subunit, and that 
hCG/LRR 4 complex interacts with exoloop 2 of the endodomain (28).  
 
In addition to the N-terminal and the LRR regions, the hinge region (Thr250-Gln268) also binds to 
hCG with affinity, preferentially to hCGα (29). The interaction between hormone and the hinge 
region is inhibited by exoloop 2 of the endodomain but not by exoloops 1 and 3, suggesting an 
intimate relationship between Thr250-Gln268, exoloop 2, and hCG (29). This hinge region is 
elucidated not only important for hormone binding but also for signal generation. When S255 was 
mutated to Ala, the mutant receptor showed 4-7 fold increased basal cAMP (30).  
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Hormone binding occurs mainly in the exodomain of the LHR with high affinity, but there is 
evidence that hormone also contacts to the endodomain with low affinity and modulates 
hormone signals. The N-terminal exodomain-truncated LHR binds to hCG with low affinity and 
produces cAMP at high hormone concentrations (9, 31), suggesting that there is a secondary 
contact of hormone/exodomain complex to the endodomain upon hormone binding, thus 
generating hormone signals from the endodomain of the receptor. The inhibition of hormone 
binding by a synthetic peptide of the exoloop 3 (Lys573-Lys583) suggests that exoloop 3 is one of 
the multiple hormone contact sites in the endodomain of the LHR (20). Our group showed the 
first physical evidence of hormone binding to the endodomain with a photoaffinity labeling of 
FSH by the exoloop 3 peptide of the FSHR (32).  
 
Hormone binding to the exodomain is also constrained by the endodomain of the LHR. 
Endodomain-truncated LHR showed twice as high hormone binding affinity (33). Site-directed 
mutagenesis studies suggest that mutations in the exoloops 2 and 3 modulate hormone binding to 
the exodomain (33, 34). There are also many mutations located in the TM region abolishing 
hormone binding (35). Our group demonstrated that hormone binding to the hinge region 
(Thr250-Gln268) is inhibited by the exoloop 2 peptide (29). Hsueh’s group showed that when 
Ser255 in the hinge region is mutated, the LHR shows constitutive activity (30).  When the hinge 
region including Ser255 and the exoloop 2 of the fly LGR was replaced by the human LHR 
counterpart, the chimeric receptor had reduced constitutive activity (36), demonstrating that the 
hinge region and the exoloop 2 of the human LHR keep the receptor in an inactivate 
conformation and that the mutation in Ser255 disrupts the conformation leading to constitutive 
activation (30). The interaction between the hinge region and the exoloop 2 was also 
demonstrated in the H3 relaxin receptor, another Leu-rich repeat-containing G protein-coupled 
receptor (37).  
 
It has been shown that hormone binding to the LHR is constrained by the endodomain. There is 
evidence in the TSH receptor that the exodomain also constrains the endodomain activity. When 
the exodomain of the TSH receptor was removed, the endodomain of the TSH receptor showed 
4-7 fold higher basal level activity in the absence of hormone (38). Serial N-terminal truncation 
of the TSH receptor showed that as the truncation proceeds towards Ser281 (corresponding to 
 5
Ser255 in the LHR), the truncated receptor showed increased constitutive activity in the absence 
of hormone (39).  This constitutive activity of the endodomain was also assumed for the LHR, 
but there is evidence that the mechanism of receptor activation of the LHR is different from that 
of the TSH receptor. First, no constitutive activity of the LHR endodomain has been reported (31, 
40, 41). Second, studies indicate that Gly109 in the LRR 4 works as an activator for signal 
generation (27) and the exodomain itself is also required for the constitutive activity of LHRS255A 
(41). 
 
Reconstitution of a functional LHR by coexpression of its split exodomain and endodomain 
shows evidence of sufficient interactions between the exodomain and the endodomain 
responsible for receptor activation and signal generation (40). The interaction between the 
exodomain and the endodomain were further investigated in this dissertation with defined-
function LHR mutants (42, 43).  
 
Taken together, hormone binding to the LHR leads to conformational changes of the 
hormone/exodomain complex and elicits hormone signals from the endodomain of the receptor 
(24). Hormone signals are considered to be generated from the hormone/receptor interface and 
the hormone/receptor conformational changes are thought to propagate through the TM to the 
cytoplasmic part of the receptor (24). When signals reach cytoloop 3 and the C-terminal tail, G 
protein α subunit is activated and released from the βγ subunits, leading to the activation of 
effector molecules (24). The LHR activates adenylyl cyclase and phospholipase Cβ to induce 
cAMP and inositol phosphate signaling, respectively (17). Gs, upon release from the LHR, is 
responsible for the activation of adenylyl cyclase. Gi2 or βγ subunit released from Gi2 is known to 
activate phospholipase Cβ (44). cAMP binds to regulatory subunits of the protein kinase A and 
activates intracellular signaling pathways, including mitogen-activated kinase pathways. Diacyl 
glycerol and IP3 generated by phospholipase Cβ also activates protein kinase C pathway and 
Ca2+ mobilization in the cell, respectively. These molecular activations of signaling molecules 
invoke cellular responses mediated by the LHR. 
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Mutations of the LHR 
 
Many important findings on the structure-function relationship of the LHR have been revealed 
with the findings of mutations in patients or through mutagenesis studies. The discovery of LHR 
mutation Lys583 to either Arg or Ala played an important role in understanding the relationship of 
hormone binding, signal generation, and signal divergence. Lys583 is located in the junction of 
TM7 and exoloop 3. Exoloop 3 is the shortest exoloop, consisting of 11 amino acids (exoloop 1 
has 21 amino acids, and exoloop 2 has 20 amino acids). When Lys583 was mutated to Arg, the 
mutant LHRK583R maintained normal cell surface expression and hormone binding affinity but 
failed to produce cAMP and inositol phosphate signaling (45, 46). Though it was suggested a 
decade earlier that receptor activation is separable from hormone binding (9), LHRK583R is the 
first mutation found in the LHR which is crucial for receptor activation but not for hormone 
binding (45). Because of the short exoloop 3 size, mutation in the exoloop 3, including the 
LHRK583R, is considered to be more sensitive compared to mutations in exoloops 1 and 2.  
 
Whn Lys583 was mutated to Ala, the mutant receptor did not produce cAMP as LHRK583R did not, 
but it produced inositol phosphate signaling similar to wild type LHR (46). This suggests that 
there are two distinct transmembrane signal conductors for cAMP and inositol phosphate signals 
in the LHR (46). The selectivity of hormone signals by the mutation of Lys583 to Arg or Ala 
further suggests that hormone signals generated from conformational changes in the 
hormone/exodomain complex are diverged in the exoloop areas.  
 
Mutations in the LHR or the FSHR cause disorders related to reproduction and secondary sexual 
characteristics including infertility and precocious puberty (35, 47).  15-16 percent of the human 
population are infertile, affecting 80 million people worldwide with 5 million in the Unites States 
alone (48, 49). While there are other factors affecting infertility, mutations in the LHR and FSHR 
cause infertility in men and women, and mutations in the LHR have been found more frequently 
than those in FSHRs. Inactivating mutations of the LHR cause Leydig cell hypoplasia with 
complete female external genitalia in the male, whereas they cause menstrual disorders, cystic 
ovaries, and infertility in the females. Activating mutations of the LHR have only been found in 
males causing precocious puberty with onset at the age of 3 to 5, thus termed male-limited 
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precocious puberty. In females, however, activating mutations of the LHRs are asymptomatic 
and do not cause any phenotypes. 
 
Inactivating mutations are found both in the exo- and endodomain of the LHR, whereas 
activating mutations are mainly found in the endodomain (35). Several inactivating mutations 
were found in the exodomain, including an insertion of 11 amino acids in the N-terminal region, 
deletion of the exon 8, and point mutations at Cys133 and Asn291 (35, 50). These do not result in 
production of cAMP due to their failure to bind hormone. Inactivating mutations in the 
endodomain mostly located in the TM5 to 7 also prevent hormone binding (35). There is no 
direct evidence yet as to how TM mutations affect hormone binding, but these endodomain 
mutations further support the evidence that hormone binding is constrained by the endodomain 
(33, 34). Most inactivating mutations are either from non-hormone binding or from reduced cell 
surface expression, and there is no report yet on a clinical mutation with normal hormone 
binding affinity but with impaired signaling like that of LHRK583R. 
 
Activating LHR mutations were found in every TM except TM3 and 7, with the majority of 
activating mutations located in TM6, known as the “hot spot” of activating LHR mutations 
(Figure 1.6). Upon ligand binding to the rhodopsin and the β2-adrenergic receptors, there is a 
movement of the cytoplasmic end of TM6 away from TM3 leading to conformational changes in 
TMs and cytoloops (51). Mutations in the TM6 hot spot area of the LHR cause constitutive 
receptor activation, not only by the disruption of interhelical bonds stabilizing the inactivate state, 
but also by the formation of new bonds that can stabilize an active state of the receptor (52). It 
was shown that the Asp578Gly mutation, the most frequently found activating LHR mutation, 
serves as a hydrogen bond acceptor. It is this, rather than a hydrogen bond donor, that is 
important for stabilizing the inactivate state of the LHR (53).  
 
Each human cell contains two copies of each chromosome, one inherited from the mother and 
one from the father, thus called homologous chromosomes. Thus, even if there is a mutation in a 
gene in one allele, the other allele of the same gene can complement the function of the mutated 
allele. However, in some patients both copies of a gene were found to be mutated. Three cases of 
mutations of the LHR gene in both alleles have been reported (54-56). The finding of these 
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compound heterozygotes provided the grounds of this dissertation to study the relationship of 
two defective heterozygous LHRs, especially the relationship between the exodomain of one 
receptor and the endodomain of the other receptor. It is of particular interest because some 
patients may have compound heterozygous LHR mutations, but the patients may not be infertile 
due to successful rescuing of signaling by complementation of two defective functions: LHR-hCG 
and LHR+hCG/-cAMP (Figure 1.8). The LHR gene is located on the chromosome 2 spanning 2p21-
26 (57). 
 
The first compound heterozygote of an LHR was reported from a patient with Leydig cell 
hypoplasia (54). The patient had three mutations: deletion of exon 8 (exodomain, LHR) in one 
allele and Asn291Ser (exodomain) and Ser616Tyr (TM7) in the other allele. Hormone binding 
assays with the exon 8 deletion showed failure of cell surface expression of the receptor. 
Transfection studies with the Asn291Ser/Ser616Tyr double mutations showed reduced cell surface 
expression and signal generation. Another case of compound heterozygous mutation was found 
in a family with two 46, XY children affected with Leydig cell hypoplasia (55). The first 
mutation, Cys545Stop in the TM5, had impaired cell surface expression and cAMP generation, 
and the second mutation, insertion of 11 amino acids in the exon 1, had reduced cAMP induction. 
The third case of compound heterozygote resulting in complete Leydig cell hypoplasia was 
reported with two mutations of Cys343Ser in the hinge region of the exodomain and Cys543Arg in 
the TM5 (56). Both mutant LHRs had normal protein level in the cytoplasm by Western blotting 
study, but cell surface expression of the mutant receptors was completely impaired, implicating 
that translocation is halted at the endoplasmic reticulum level blocking further processing to the 
cell surface.  In addition to the LHR mutations, three cases of compound heterozygous FSHR 
mutations have been reported (58-60). 
 
Goal of Dissertation 
 
This dissertation has three goals. The first goal is to elucidate whether the LHR, upon hormone 
binding, activates other unoccupied LHRs inter-molecularly for the rescue of cAMP signaling 
(trans-activation) (Figure 1.8). This is particularly important considering that there are patients 
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with compound heterozygotes of LHRs (54-56) or FSHRs (58-60), and the relationship between 
the compound heterozygous LHR or FSHR is unknown. 
 
Second, I want to find whether or not the LHR also activates other unoccupied LHRs for inositol 
phosphate signaling as well as cAMP signaling. This is of interest because the LHR activates 
both cAMP and inositol phosphate signaling, but the activation requires different hormone 
concentrations and mechanisms. 
 
Finally, this dissertation will discuss whether or not a single LHR activates both Gs and Gi2 
molecules simultaneously or individually. Although the LHR generates both cAMP and inositol 
phosphate signaling, their temporal relationship has not yet been studied. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © ChangWoo Lee 2003 
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Figure 1.1   Crystal structure of hCG. hCG α (92 amino acids) is shown in red, and hCG β 
(145 amino acids) in green. The seat belt region of hCG β is shown in blue, wrapping around the 
α subunit stabilizing the heterodimers. 
 11
 
 
 
 
 
 
 
 
 
Figure 1.2   Schematic diagram of the LHR. The N-terminal exodomain consists of ~350 
amino acids and binds to hormone with high affinity. An equal-sized endodomain is membrane-
associated and is responsible for signal generation. 
 12
 
 
 
 
 
 
 
 
 
Figure 1.3   Important regions of the LHR for hormone binding. Hormone binds to the N-
terminal cysteine-rich region, Leu-rich repeat (LRR) region, and the C-terminal hinge region. 
Adapted from Nakabayashi et al. (2000) J Biol Chem 275, 30264-71 (30). S277 in the human 
LHR corresponds to S255 in the rat LHR. 
 13
 
 
 
 
 
 
Figure 1.4   Side and top view of the LHR endodomain. TMs are located counterclockwise 
and connected by exoloops and cytoloops. Cytoloops are not shown in the figure. 
 14
 
 
 
 
 
 
 
 
 
Figure 1.5   Receptor activation and signal generation of the LHR. Hormone binding to the 
exodomain undergoes conformational changes in the hormone/exodomain complex and 
modulates the endodomain to generate signals. The LHR activates adenylyl cyclase and 
phospholipase Cβ to induce cAMP and inositol phosphates, respectively. 
 15
 
 
 
 
 
 
 
Figure 1.6   Mutations of the human LHR. Amino acids relevant for hormone binding, 
inactivating, and activating mutations are denoted with different colors. Due to a different 
numbering custom between human and rat LHR, subtract 22 to find the corresponding amino 
acid in the rat LHR from the above sequence. 
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Figure 1.7   Defined-function mutants in the LHR used in this dissertation to access 
receptor-receptor interactions. L20A, C22A, I55A, and I80A (LHR-hCG) are located in the 
exodomain. P479A and P479G (LHR-hCG) are located in the TM4. K583R is located in the junction 
of exoloop 3 and the TM7 (LHR+hCG/-cAMP). 
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Figure 1.8   Cis-activation and trans-activation of LHRs. A. Domain structure of LHR 
showing the exodomain where the ligand binds and the endodomain where the hormone signal is 
generated. B. Cis- and trans-activation of monomeric LHRs. The ligand is shown in red. C. Cis- 
and trans-activation of dimeric LHRs. D. Trans-activation of a mutant LHR that is defective in 
ligand binding in the exodomain (blue) but is capable of generating a hormone signal in the 
endodomain (gray) (LHR-hCG/+cAMP) by a mutant LHR that is capable of binding ligand in the 
exodomain (gray) but incapable of generating a hormone signal in the endodomain (blue) 
(LHR+hCG/-cAMP). 
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Chapter 2     Trans-activation of the LHR for cAMP Signaling 
 
Introduction 
 
The luteinizing hormone receptor (LHR) plays a crucial role in the development of the gonads in 
both sexes and ovulation in females. Defective mutations of the receptor often cause infertility 
(61). Gain of function mutations are generally dominant, whereas loss of function mutations are 
recessive. The genetic prediction of mutations is not straightforward, because the effects of some 
mutations are partial and some patients are defective heterozygotes. For example, there are 
patients with two defective heterozygous LHR mutations (54-56) and the precise relationship of 
two mutant receptors in a patient is unclear. This is particularly relevant for LHR, which has two 
distinct domains, one for hormone binding and the other for signal generation (7, 62, 63).  
 
We wondered about the relationship between the two alleles as to whether they would be 
dependent on or independent of each other. Particularly, there is the intriguing possibility that 
two heterozygous mutants, one defective in hormone binding and the other with normal hormone 
binding but defective signal generation, might interact with each other to rescue hormone action 
(Figure 1.8). Obviously, this would require the novel intermolecular interaction of the exodomain 
of one LHR with the endodomain of another LHR. Although it has never been described, it 
would have significant impact on the interpretation of receptor genetics and provide new insights 
into clinical treatments. To test this hypothesis, various heterozygous defective LHRs were 
paired and tested for their functional rescue were coexpressed. 
 
Materials and Methods 
 
Mutagenesis 
 
Mutant rat LHR cDNAs were prepared in a pSELECT vector using the non-polymerase chain 
reaction-based Altered Sites Mutagenesis System (Promega). The multiple cloning site of the 
vector was cut with XbaI and BamHI, and then uni-directionally ligated with full-length rat LHR 
cDNA. Single strand DNA was prepared, and mutagenesis was performed according to the 
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manufacturer’s instruction. Oligonucleotides were purchased from Biosource. Vectors containing 
mutant LHR constructs were selected by ampicillin screening. After confirming mutations by 
sequencing, the mutant cDNAs were subcloned into the BamHI and XbaI sites of 
pcDNA3/neomycin (Invitrogen), a eukaryotic expression vector. 
 
Plasmid Purification 
 
Wild type or mutant LHR cDNAs prepared through mutagenesis was transformed into TOP10 
competent cells (Invitrogen) using Gene Pulser II electroporator (Bio-Rad) and plated onto 
LB/ampicillin (125 µg/ml) plates. LHR plasmid DNAs were purified by CsCl/ethidium bromide 
equilibrium centrifugation or by large-scale plasmid kits (QIAGEN and Bio-Rad). 
 
Transfection 
 
Varying concentrations of plasmids were transfected into human embryonic kidney (HEK) 
293 cells by the calcium phosphate method (64). Briefly, 6-24 µg of plasmid DNA was added 
into 1.7 ml tube containing 250 µl of 0.25 M CaCl2 followed by 250 µl of 2X BES. The mixture 
was vortexed shortly, incubated for 8-12 min at room temperature, and transferred into T25 flasks 
(Corning) of cultured cells drop by drop. Transiently transfected cells were assayed 60-72 h after 
transfection. Stable cell lines were established in minimum essential medium (MEM) containing 
8% horse serum and 500 µg/ml G-418. All assays were carried out in duplicate and repeated 
three to four times (n = 6-8). Means and standard deviations were calculated.  
 
cAMP Assay 
 
Cells were washed twice with MEM and incubated in the medium containing 
isobutylmethylxanthine (0.1 mg/ml) for 15 min. Increasing concentrations of hCG were then 
added, and the incubation was continued for 45 min at 37 °C. After the medium was removed, 
the cells were rinsed once with fresh medium without isobutylmethylxanthine, lysed in 70% 
ethanol, freeze-thawed in liquid nitrogen, and scraped. After pelleting cell debris at 16,000 × g 
for 10 min at 4 °C, the supernatant was collected, dried under vacuum, and resuspended in 10 µl 
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of the cAMP assay buffer provided by the 125I-cAMP assay kit (Amersham Biosciences). cAMP 
concentrations were determined following the manufacturer's instruction and validated for use in 
our laboratory.  
 
Iodination of Hormones and Antibodies 
 
hCG (CR-127) and human FSH (AFP-7298A), provided by the National Hormone and Pituitary 
Program, were radio-iodinated as described previously (65). Briefly, 50 µl of phosphate-buffered 
saline (pH 7.4) was added to 3 to 8 µg of hCG. To this solution were added 7 µl of chloramine-T 
(0.33 mg/ml) and 1 mCi (1 Ci = 3.7 × 1010 becquerels) of sodium [125I]iodide in 10 µl of 0.1 M 
NaOH; 20 sec later, iodination was stopped by addition of 7 µl of sodium metabisulfite (0.66 
mg/ml). The iodinated hCG (125I-hCG) was immediately fractionated on a Sephadex G-50 
(superfine) column (0.6 × 15 cm). Radio-activity of each fraction was measured in a gamma 
counter (Beckman) and the fraction of highest radio-activity was kept at 4 °C for hormone 
binding assays. Specific activity of 125I-hCG was in the range of 60,000 - 80,000 cpm/ng of hCG. 
 
Hormone Binding Assay 
 
Cells were washed twice with medium, MEM with 20 mM of HEPES, pH 7.4 and  0.1 g/100 ml 
of bovine serum albumin. Cells were assayed for 125I-hormone (150,000 cpm) binding in the 
presence of increasing concentrations of non-radioactive hormone for 90 min at 37 °C. Cells 
were washed twice with medium, solubilized with 1 N NaOH, and collected in glass culture tube 
followed by measurement in a gamma counter (PerkinElmer) for 10 min. Non-specific binding 
(usually less than 1 % of specific binding) was determined by replacing 125I-hormone with 
excessively higher concentrations of hormone. Kd values and number of receptors were 
determined by Scatchard plots.  
 
Radioimmunoassay for Flag-LHR 
 
Flag-LHR was prepared by inserting the Flag epitope, Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys (5-
GAC TAC AAG GAC GAT GAC GAT AAG-3), between the C terminus of the signal sequence 
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and the N terminus of mature receptors. Mouse anti-Flag monoclonal M2 antibody (Sigma) was 
iodinated with 125I according to the published procedure for radio-iodination of hCG (65), and 
125I-anti-Flag antibodies were purified on a Sephadex G-150 column. Binding of 125I-anti-Flag 
(150,000 cpm) to HEK 293 cells expressing Flag-LHRs was carried out in the presence of 
increasing concentrations of non-radioactive anti-Flag antibody in MEM containing 3 mg/ml of 
bovine serum albumin for 8-10 h at 4 °C. 125I-anti-Flag antibody (65) was used to determine the 
concentrations of receptors incapable of binding the hormone, in comparison with 125I-hCG used 
to determine the concentration of receptors capable of binding the hormone. 
 
Results 
 
To investigate the interaction of heterozygous mutant LHRs, we chose the K583R mutant 
(LHRK583R) in which Lys583 was substituted with Arg. This mutant receptor is normally 
processed and targeted to the cell surface and is capable of binding hCG but incapable of 
inducing cAMP production (45). The mutant receptor is referred to as LHR+hCG/-cAMP. In addition 
to the LHR+hCG/-cAMP, other mutant LHRs were selected that were expressed on the cell surface 
but were incapable of binding hCG (LHR-hCG). They are L20A, C22A, P479A, and P479G mutants 
(21, 66). HEK 293 cells transiently transfected with the LHRK583R plasmid showed hCG binding 
with the wild type affinity but did not produce cAMP in response to increasing doses of hCG 
(Figure 2.1). Cells transiently transfected with the plasmid for LHRL20A, LHRC22A LHRP479A, or 
LHRP479G did not show hCG binding or cAMP induction, consistent with previous reports (21, 
66). The cells transfected with the blank plasmid, pcDNA3, failed to bind hCG and produce 
cAMP, indicating that the vector itself was not involved in hCG binding.  
 
Next, cells were co-transfected with a pair of LHR+hCG/-cAMP and LHR-hCG, for example, K583R 
and L20A mutants or K583R and C22A mutants. The cells that were co-transfected with either 
LHRK583R and LHRL20A or LHRK583R and LHRC22A were capable of binding hCG, and the Kd 
values were similar to the wild type value (Figure 2.2, A and B). In addition, these cells induced 
cAMP production in an hCG dose-dependent manner (Figure 2.2, C). The maximal levels of 
cAMP were approximately one-third of the wild type value, and their EC50 values were 15-25-
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fold higher than the wild type value (Figure 2.2, table), suggesting the rescue of cAMP induction 
with lower potency.  
 
The data shown in Figure 2.2 suggest that the non-binding receptors were expressed on the cell 
surface, as rigorously demonstrated by different methods in previous reports (21, 66). However, 
to validate the surface expression, cells were transfected with the mutant receptors that carry the 
Flag epitope at the N terminus (Flag-LHRC22A) and assayed for binding of anti-Flag monoclonal 
antibody as described previously (21, 26). The cells were incubated with 125I-anti-Flag 
monoclonal antibody with increasing concentrations of non-radioactive antibody. The cells 
showed specific binding of the 125I-antibody, which was gradually displaced by non-radioactive 
antibody, as did the cells transfected with Flag-LHRWT (Table 2.2). However, there was no 
specific antibody binding to the cells transfected with the LHRWT, LHRC22A, or LHRL20A plasmid 
as previously reported (21). These results show that the Flag-LHRs were indeed expressed on the 
cell surface in these experiments. To determine whether Flag-LHRC22A can rescue cAMP 
induction, it was coexpressed with LHRK583R. As expected, the cells bound hCG and produced 
cAMP (Figure 2.3).  
 
It is unclear whether cAMP was induced by accidental collisions between the endodomains of 
two different mutant receptors. To test this possibility, several pairs of two different LHR-hCG 
mutants were coexpressed. As shown in Figure 2.4, none of the coexpressed pairs (LHRC22A and 
LHRL20A, LHRC22A and LHRP479A, LHRC22A and LHRP479G, LHRL20A and LHRP479A, and LHRL20A 
and LHRP479G) was capable of inducing cAMP or binding hCG. These results show that one of 
the mutant pairs has to be capable of binding hCG to rescue cAMP induction.  
 
To test the dependence of the rescue on hCG binding, cells were co-transfected with varying 
concentrations (6, 12, and 18 µg) of the LHRK583R plasmid and a constant amount (6 µg) of the 
LHRL20A or LHRC22A plasmid. The cells were assayed first for hCG binding to determine the 
relationship of the surface concentration of LHRK583R with the plasmid concentration (Figure 2.5). 
The results show that the surface concentration of LHRK583R increased in parallel to the plasmid 
concentration used for transfection. The range of the LHRK583R concentration was 5,000-21,000 
receptors/cell, which compares favorably with the in vivo LHR concentration on porcine 
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granulosa cells and rat Leydig cells, several thousand per cell (15-17). In addition, the variation 
in the receptor concentration does not appear to impact the hormone binding affinity. However, 
the maximum cAMP levels show an interesting trend. When 6 µg of the LHRL20A plasmid was 
co-transfected with 6, 12, or 18 µg of the LHRK583R plasmid, the maximum cAMP levels were 
52.4, 71.1, and 36.5 fmol/1000 cells, respectively. The differences among the three values are 
statistically significant with p values of <0.05 to <0.001. Therefore, the maximum cAMP level 
increased by 36% at 12 µg and then decreased by 30% at 18 µg as compared with the cAMP 
level at 6 µg of the plasmid. The result was similar when 6 µg of the LHRC22A plasmid was co-
transfected with 6, 12, or 18 µg of the LHRK583R plasmid. These observations suggest that the 
cAMP rescue requires LHRK583R and is dependent on the concentration of this mutant receptor. 
 
One may question whether the surface expression levels of the LHR-hCG mutants shown in Figure 
2.5 were constant, although 6 µg of the plasmids was used for transfection of the cells throughout 
the experiment. To address this problem, we took another approach to keep the expression level 
of LHR-hCG mutants constant. Cell lines were established after stably transfecting them with the 
LHRL20A plasmid or LHRC22A plasmid. These cell lines were transfected again with varying 
concentrations (6, 12, and 18 µg) of the LHRK583R plasmid. The doubly transfected cells showed 
increasing concentrations of LHRK583R (Figure 2.6). Transfection with 12 µg of the LHRK583R 
plasmid increased the maximum cAMP level by 29-58% over that of the cells transfected with 
6 µg of the plasmid. Transfection with 18 µg of the plasmid resulted in a 3-fold increase in the 
EC50 value for the cAMP rescue, although the maximum cAMP levels remained high. The 
observations described in Figures 2.6 and 2.7 indicate that the cAMP rescue is dependent on the 
LHRK583R concentration. However, there is a notable difference in the results of Figures 2.6 and 
2.7. In Figure 2.5 the maximum levels of cAMP peaked as the LHRK583R concentration increased, 
whereas it plateaued in Figure 2.6. The difference in the two experiments was LHR-hCG, which 
was transiently expressed in the Figure 2.5 experiment and stably expressed in the Figure 2.6 
experiment. A molecule is expressed in stable cell lines generally more than in transiently 
expressing cells because of the associated antibiotic selection. Therefore, another experiment was 
performed using the stable cell line expressing Flag-LHRC22A, which appears to express less than 
12,800 receptors/cell. It was transiently transfected with increasing concentrations of the 
LHRK583R plasmid from 3 to 18 µg. The cells produced cAMP in response to hCG, and the 
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maximum cAMP levels peaked (Figure 2.3). These results taken together with the data shown in 
Figures 2.6 and 2.7 show that there are optimal concentrations of LHRK583R to pair with LHR-hCG 
and rescue cAMP induction. They indicate the importance of the number of the hCG binding 
receptor and/or the ratio of the hCG binding receptor to the non-binding receptor.  
 
The non-binding receptors tested so far have mutations in the exodomain that impair hormone 
binding. In addition to these non-binding receptors with a defective exodomain, there are non-
binding receptors that have a normal exodomain but mutation in the endodomain, such as P479A 
and P479G of the transmembrane helix 4 (66). These mutations in the endodomain block hCG 
binding to the exodomain by constraining the exodomain although the exodomain itself is intact 
(33, 34). To test whether these mutants could pair with LHRK583R and induce cAMP production, 
LHRK583R was coexpressed with LHRP479A or LHRP479A. The cells co-expressing LHRK583R and 
LHRP479A or LHRK583R and LHRP479A failed to induce cAMP production although they were 
capable of binding hCG (Figure 2.6). These results indicate that not all of the mutant pairs of 
LHR-hCG and LHR+hCG/-cAMP are capable of rescuing the hCG dependent cAMP induction, 
suggesting a specificity for pairing. Furthermore, these results suggest that LHR-hCG with a 
mutation in the exodomain, but not in the endodomain, could be rescued.  
 
In addition, we tested the affect of another receptor species on the activity of wild type LHR. 
When LHRWT was coexpressed with FSHRWT, the functional FSHR did not impact the hCG 
binding affinity or the EC50 value and maximum level of cAMP induction by LHRWT (Figure 
2.8). These results show that the cAMP induction by LHR-hCG and LHR+hCG/-cAMP was not 
rescued by accidental collisions between them or with different hormone receptor species. 
 
Discussion 
 
The observations described in this dissertation show that cells co-expressing a pair of two 
differently defective mutants, one defective in hCG binding at the exodomain (LHR-hCG) and the 
other defective in signal generation at the endodomain (LHR+hCG/-cAMP), can induce cAMP 
production. This successful rescue of cAMP induction requires both types of mutant receptors. 
However, not all LHR-hCG were capable of pairing with LHRK583R, an LHR+hCG/-cAMP, and 
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rescuing cAMP induction. Rescue is observed when hormone binding of an LHR-hCG is impaired 
by a mutation in the exodomain but not by mutations in the endodomain. These results suggest 
specificity for the rescue of cAMP induction. For example, the rescue is dependent on hCG dose, 
the surface concentration of the mutant receptors, and the amino acid positions of the mutations. 
Furthermore, random collisions among mutant receptors are not involved in the rescue.  
 
It is known that LHR binds hCG first at the exodomain (9, 19, 67), and the resulting hCG-
exodomain complex undergoes conformational changes (68-70) and modulates the endodomain 
(29, 30). This secondary interaction is responsible for signal generation and receptor activation (7, 
62, 63). Based on these observations and the results described in this dissertation, the cooperation 
between the two types of mutant LHRs includes the exodomain of LHRK583R and the endodomain 
of LHRL20A or LHRC22A. Furthermore, the two domains most likely interact with each other. 
Therefore, the results suggest an intermolecular interaction (trans-activation) between the 
exodomain of one receptor and the endodomain of another receptor and implicate at least partial 
substitution of the hCG-functional exodomain complex of a receptor for the defective exodomain 
of another receptor. This is appealing if LHR form dimmers. In a dimeric situation, a liganded 
LHR could cis-activate itself and then, trans-activate its partner LHR in the dimmer. However, 
the existing crosslinking and immunological evidence do not support oligomerization of LHRs.  
 
The intermolecular exodomain-endodomain interaction is also consistent with the dependence of 
the rescue on receptor concentrations and the existence of optimal concentrations. The 
observation that too few or too many LHR+hCG/-cAMP can interfere with the collaboration between 
LHR+hCG/-cAMP and LHR-hCG is of interest and reminiscent of the antibody and antigen interaction. 
Too many LHR+hCG/-cAMP would nonproductively compete for a limited number of LHR-hCG, 
which could lead to less effective induction of cAMP. 
 
Previous studies on the dose-response relationship between hCG binding and hCG-stimulated 
cAMP and steroidogenesis indicate that cellular responses, such as testosterone synthesis in 
Leydig cells, reach their maximum at very low hormone concentrations and had no effect upon 
cAMP production (15, 71, 72). Hormone occupancy of only 1-3% of the receptor sites was 
enough to induce maximum steroidogenesis, and specific hormone binding was undetectable at 
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these low hormone concentrations (1-2 pM) (15). The EC50 of cAMP induction (50 pM) was ten 
times lower than the EC50 of hCG bound (500-600 pM) (15). The presence of these > 97% 
“unbound” receptors are referred to as "spare receptors". The term does not imply that these 
receptors are not utilized; rather, a maximum biological response is achieved when 1-3% of 
receptors are occupied. The importance of these spare receptors is that they compensate for low 
concentrations of hormone in physiological conditions and remove excess hormones soon after 
hormone action, a necessary step. When the spare receptor number decreases, the EC50 for 
cAMP induction increases, requiring more hormone for the same maximal cAMP induction (73). 
The difference of hCG concentrations required for half-maximal cAMP production and half-
maximal occupancy of receptor sites, along with the absence of direct evidence of increased 
adenylyl cyclase activity during stimulation of steroidogenesis by low hCG concentrations have 
raised the possibility that other membrane-associated responses may be involved during the 
initial phase of gonadotropin-induced steroidogenesis in the Leydig cell (15, 74). The data from 
this dissertation suggests the intriguing possibility of intermolecular trans-activation of other 
unoccupied LHRs by a liganded LHR, in addition to intramolecular cis-activation of its own 
endodomain. It is tempting to speculate that pleiotropic trans-activation of the LHRs might lead 
to maximum steroidogenesis with hormone occupancy on 1% of the receptor sites. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © ChangWoo Lee 2003 
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Table 2.1     Surface expression of Flag-LHRs 
 
Cells were transfected with various Flag-LHR plasmids and assayed for 125I-monoclonal anti 
Flag-antibody binding in the presence of increasing concentrations of unlabeled antibody as 
described under "Materials and Methods." Specific antibody bindings were determined and 
compared with the specific binding of the Flag-LHRWT. 
 
 
125I-anti-Flag mAb 
Binding (%) 
LHRWT                   5 ± 3 
Flag-LHRWT               100 ± 9 
Flag-LHRL20A                 91 ± 17 
Flag-LHRC22A                 60 ± 15 
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Figure 2.1   Activity of mutant receptors. HEK 293 cells were transiently transfected with 
pcDNA3, a eukaryotic expression vector, or the vector with the wild-type LHR and various 
mutants. The cells were assayed for 125I-hCG binding in the presence of increasing 
concentrations of unlabeled hCG (A). The results were converted to Scatchard plots (B). In 
addition, the cells were treated with increasing concentrations of unlabeled hCG, and 
intracellular cAMP was measured (C) as described under "Materials and Methods." The 
experiments were performed in duplicate and repeated three to four time (n=6-8). The means and 
standard deviations are presented in the table (below panels A-C). NS, not significant. 
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Figure 2.2   Coexpression of LHR-hCG and LHR+hCG/-cAMP. HEK 293 cells were transiently 
coexpressed with an LHR defective in hCG binding and an LHR defective in cAMP induction 
and were assayed for hCG binding and cAMP induction as described in the legend for Figure 2.1. 
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Figure 2.3   Coexpression of Flag-LHRC22A and LHRK583R. Cells stably expressing Flag-
LHRC22A were transfected with increasing concentrations of the LHRK583R plasmid. The cells 
were assayed for hormone binding and cAMP induction as described in the legend for Figure 2.1. 
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Figure 2.4   Specificity of cAMP rescue. Cells were transiently coexpressed with various 
combinations of LHR-hCG and assayed for hormone binding and cAMP induction as described in 
the legend for Figure 2.1. 
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Figure 2.5   Receptor concentration-dependent cAMP rescue. Cells were transiently 
cotransfected with varying concentrations of the LHRK583R plasmid and 6 µg of the LHRC22A or 
LHRL20A plasmid. The cells were assayed for hormone binding and cAMP production as 
described in the legend for Figure 2.1. 
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Figure 2.6   Coexpression of stable LHR-hCG and transient LHR+hCG/-cAMP. Cells stably 
expressing LHR-hCG were transiently transfected with increasing concentrations of the LHRK583R 
plasmid. The cells were assayed for hormone binding and cAMP production as described in the 
legend for Figure 2.1. 
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Figure 2.7   cAMP rescue is dependent on the location of mutation in LHR-hCG. Cells were 
transiently coexpressed with LHRK583R and LHRP479A or LHRK583R and LHRP479G. The cells were 
assayed for hormone binding and cAMP production as described in the legend for Figure 2.1. 
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Figure 2.8   Coexpression of LHRWT and FSHRWT. 12 µg of FSH receptor plasmid was 
transiently transfected into HEK 293 cells stably expressing LHRs. The cells were assayed for 
hormone binding and cAMP production as described in the legend for Figure 2.1. 
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Chapter 3     No Trans-activation of the LHR for IP Signaling 
 
Introduction 
 
Many hormone receptors, including those for glycoprotein hormones, activate multiple 
intracellular signals such as cAMP, inositol phosphate, and Ca2+  through their promiscuous 
couplings to diverse G proteins. It has been known since the 1970s that cAMP is released by rat 
Leydig cells during gonadotropin stimulation (71, 75), and thereafter cAMP has been recognized 
as a primary second messenger of LH action in the theca and granulosa cells and in the corpus 
luteum (52). A decade later it became known that the LH also affects phosphoinositide 
metabolism in rat granulosa cells (76). The LHR was reported to be dually coupled to adenylyl 
cyclase and phospholipase Cβ (77). Gs and Gi were revealed to activate adenylyl cyclase and 
phospholipase Cβ, respectively, upon hormone stimulation (78, 79). It was further identified that 
the LHR activates phospholipase Cβ via preferential coupling to Gi2 (44), although 
phospholipase Cβ stimulation is considered to generally be activated by the βγ subunit (80). 
 
Though the cellular responses by the LHR are mediated by both adenylyl cyclase and 
phospholipase Cβ, the LHR preferentially activates adenylyl cyclase with 100-fold lower EC50 
than the activation of phospholipase Cβ (17). LH is responsible for the final maturation of the 
ovarian follicles and estrogen secretion (81). It is also responsible for ovulation, the initial 
formation of the corpus luteum, and secretion of progesterone (81). Intracellular cAMP is known 
to be mainly responsible for the expression of specific genes involved in the LH action (81). 
 
The physiological role of the phospholipase Cβ pathway is not clearly defined yet. The 
activation of phospholipase Cβ by the LHR requires high hormone concentrations (EC50: 1-10 
nM) and large receptor numbers (17, 46, 82) compared with the activation of adenylyl cyclase. 
This suggests that the phospholipase Cβ pathway exists in granulosa cells in females. However, 
one wonders whether it is active in Leydig cells, because the hCG/LH concentrations are 
generally below the EC50 values. A study on the impairment of ovulation in rats with PKC 
inhibitors supports the role of the phospholipase Cβ pathway in ovulation (83). These three 
 37
signaling pathways,  cAMP, inositol phosphate, and protein kinase C, stimulated by the LHR 
have been reported to be independent of each other. Pretreatment with a physiological activator 
of protein kinase C, PGF2α, had no effect on LH-stimulated inositol phosphate accumulation 
(84), and neither forskolin nor prostaglandin E1, which both increase cAMP levels in L cells, had 
an effect on inositol phosphate accumulation and Ca2+ elevation in L cells (17). 
 
Another clue in the role of the inositol phosphate signaling from the LHR comes from a clinical 
LHR mutant (Asp578His) causing Leydig cell tumors (85). This mutation is located in the TM6 
(Figure 1.6). Normally, hormone-mediated activation of the LHR in Leydig cells does not result 
in the stimulation of the phospholipase Cβ pathway due to the absence of high concentrations of 
LH, unlike in granulosa cells (5). The main feature that distinguishes the Asp578His mutation 
from other LHR Asp578 mutations associated with male-limited precocious puberty is its ability 
to elevate both the basal cAMP and IP levels in the absence of hormone (85). Other LHR 
mutants such as Asp578 to Gly, Leu, Pro, and Tyr, constitutively activate only cAMP signaling 
pathway (47). The different clinical phenotype of Leydig cell adenoma by the LHR Asp578His 
mutation suggests distinct physiological functions of adenylyl cyclase and phospholipase Cβ 
pathways in LH signaling and also suggests the role of the phospholipase Cβ signal.  
 
It has been demonstrated that trans-activation of LHRs lead to the activation of adenylyl cyclase 
to induce cAMP in the previous studies (42, 43). We wondered whether the trans-activation of 
the LHR also leads to the activation of phospholipase Cβ. It is an intriguing question in regard to 
multiple hormonal signal generation because the LHR activates both adenylyl cyclase and 
phospholipase Cβ, but they require different hormone concentrations. 
 
The LHR-hCG and LHR+hCG/-IP mutants were utilized to elucidate the possibility of inositol 
phosphate signaling rescue by trans-activation of the LHR. A strategy of transient expression of 
two defective LHRs in HEK 293 cells, which at the same condition successfully rescued cAMP 
signaling, was used with high hCG concentrations of up to 1-10 µM. Also HEK 293 cells stably 
expressing both defective LHRs were established to facilitate high cell surface expression and 
assayed for the rescue of inositol phosphate signaling.  
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Materials and Methods 
 
Inositol Phosphate Assay-- Stable cells were plated in 12-well plates and grown in inositol-free 
Dulbecco's modified Eagle's medium (Atlanta Biologicals) supplemented with 8% heat-
inactivated horse serum and 2 µCi/ml [3H]inositol (PerkinElmer Life Sciences) for 48 h to 40-
50% confluency. After removing the medium, the cells were incubated in 1 ml of fresh wash 
buffer consisting of Dulbecco's modified Eagle's medium without inositol and 15 mM HEPES 
(pH 7.3) for 1 h at 37 °C. This medium was removed, and 0.3 ml of wash buffer containing 
20 mM LiCl was added and incubated for 15 min at 37 °C. After the cells were stimulated with 
increasing concentrations of hormone for 30 min at 37 °C, the incubation was terminated by the 
removal of medium and the addition of 0.25 ml of 0.6 N HCl to each well. The cells were scraped 
and transferred into microcentrifuge tubes, and the wells were again washed with 0.25 ml of 
0.6 N HCl. The combined washes were treated with 0.9 ml of a mixture of chloroform:methanol 
(2:1), vortexed, and centrifuged at 1000 × g for 5 min at room temperature. The top aqueous 
layer, which was free of phospholipids, was removed, and the remaining chloroform layer was 
treated with 0.2 ml of methanol:water (1:1), vortexed, and centrifuged, as above. This aqueous 
layer was added to the previous aqueous layer, and the samples were dried in a vacuum 
concentrator. The dried samples were redissolved in 0.5 ml of 50 mM Tris-HCl, pH 8, and 
applied to Dowex AG 1-X8 formate (Bio-Rad) columns. The microcentrifuge tubes were washed 
twice with 0.5 ml of the same buffer, and the washes were applied to the columns for a total of 
1.5 ml. The columns were sequentially washed with 4.5 ml of H2O and 4.5 ml of 60 mM 
ammonium formate and 5 mM sodium tetraborate to elute the free inositol and the glycerol 
phosphatidylinositol, respectively. IP1, IP2, and IP3 were sequentially eluted with 4 ml of 0.1 N 
formic acid in 0.2, 0.75, and 1.1 M ammonium formate, respectively, and collected in 1-ml 
fractions. Aliquots of 200 µl were counted for radioactivity in 1.5 ml of Ultima AF scintillation 
fluid (Packard). Peak radioactivities were used for the data analysis.  
 
Hormone binding assay and intracellular cAMP assay procedures are same as described in 
"Materials and Methods" of the Chapter 2. 
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Results 
 
Mutant LHRs used to successfully rescue cAMP induction in Chapter 2 and in our previous 
publications (42, 43) were selected to determine whether or not the rescuing of cAMP signaling 
by trans-activation of LHRs would also activate phospholipase Cβ and IP signaling. The non-
binding LHRs were L20A, C22A, I55A, and I80A (LHR-hCG). LHRs defective in signaling were 
K583R and ExoCD (LHR+hCG/-cAMP/-IP). The ExoCD is a chimera with a functional LHR 
exodomain linked to the non-functional CD 8 transmembrane and cytoplasmic domain (86) 
(Figure 3.1). HEK 293 cells stably expressing these mutant LHRs were established, and the 
induction of inositol phosphate was measured in the presence of hCG (Figure 3.2). None of these 
mutant LHRs showed any  elevated basal level. IP subspecies (IP1, IP2, and IP3) were also 
measured but failed to show any increase. 
 
Studies on IP induction by the LHR have revealed that two conditions are required: high hCG 
concentrations and large receptor numbers (17, 46). To check this, HEK 293 cells stably 
expressing wild type LHRs were established. Transfection studies showed that IP induction 
required high receptor concentrations on the cell surface (Figure 3.3). Cells stably expressing 
receptors usually show high receptor expression due to antibiotic selection (> 140,000 
receptor/cell in this study). However, cells transiently transfected with 12 µg of LHR plasmid 
show about 12,000 receptors per cell. The data in the Figure 3.3 shows that IP induction is also 
dependent on receptor concentrations. Net cpm increase of IP induction in stable cells is 4-5 fold 
higher than that in cells transiently expressing the receptors. To study whether those mutant LHR 
combinations which successfully rescued cAMP induction in the previous chapter, in 
physiological range of receptor numbers (6,000 – 20,000 receptors/cell), also rescues IP 
induction, the same transient transfection method was utilized. Also HEK 293 cells stably 
expressing both mutant receptors were selected and assayed for IP induction. 
 
First, 12 µg of LHRK583R were transiently transfected into HEK 293 cells with 6 µg each of 
LHRL20A, LHRC22A, LHRI55A, and LHRI80A. Trans-activation between the two receptors rescued 
cAMP induction up to 27-41% of the max cAMP induction by wild type LHR but failed to  
induce IP production (Figure 3.4). IP subspecies (IP1, IP2, and IP3) induction was also measured 
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but none was found.  Our group showed that ExoCD had slightly higher cAMP induction than 
LHRK583R when coexpressed with non-binding LHRs (43). Thus, ExoCD was coexpressed with 
LHRL20A, LHRC22A, LHRI55A, or LHRI80A transiently in HEK 293 cells (Figure 3.5). Up to 10 µM 
of hCG was added to see whether this extremely high concentration of hormone stimulates LHRs 
for IP induction. However, no induction of IP signaling including IP1, IP2, and IP3 was seen. 
 
Next, HEK 293 cells stably expressing LHRL20A or LHRC22A were transiently transfected with 
increasing concentrations of LHRK583R plasmids (6 to 18 µg) (Figure 3.6), but there was no IP 
induction, contrary to the successful cAMP induction. HEK 293 cells stably expressing 
LHRK583R were also established, and LHRL20A or LHRC22A was transiently transfected, but there 
was no IP induction. 
 
To make sure two defective LHRs are expressed in HEK 293 cells in high concentrations, HEK 
293 cells stably expressing ExoCD and LHRI55A were established and selected by G-418. hCG 
binding to cell surface ExoCD showed more than 130,000 receptors/cell, but there was no IP 
induction (Figure 3.7). In addition to this, another HEK 293 cell line stably expressing ExoCD 
and LHRI80A was also established and assayed for IP signaling but failed to induce any IP 
production. These HEK 293 cells had two mutant LHRs in the same G-418 resistance vector. 
Though they rescued cAMP signaling very successfully in the previous chapter, there was a 
chance that these cells used for IP rescuing might not have had both receptors on the cell surface. 
To ensure the expression of both mutant receptors, another stable HEK 293 cell line expressing 
both receptors with different antibiotic selection was established. Even with ExoCD in the 
hygromycin B resistance vector and LHRI55A or LHRI80A in the G-418 resistance vector, there 
was again no IP induction (data not shown). 
 
LHRP479A or LHRP479G did not induce cAMP in the previous chapter when they were coexpressed 
with LHRK583R. However, it is still possible that they may rescue IP induction by a different 
trans-activation mechanism. To test this possibility, LHRP479A or LHRP479G was coexpressed with 
LHRK583R transiently in HEK 293 cells and assayed for IP induction. No IP induction was 
observed up to 1 µM of hCG concentration (Figure 3.8). 
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The absence of IP induction from the stably and transiently coexpressed pairs of LHRs which 
successfully rescued cAMP signaling suggest the possibility that mutant LHRs  might had 
impaired the G proteins associated with the IP signaling. LHRWT was coexpressed with LHRI80A 
and with LHRI80A and LHRK583R, but the coexpressed of mutant LHR(s) did not affect IP 
induction of the wild type LHR (Figure 3.9), suggesting the absence of IP induction is not due to 
the impairment of G proteins by mutant LHRs. 
 
Discussion 
 
The results described in this chapter show that a liganded LHR exodomain was capable of trans-
activating the endodomain of some unliganded LHRs and stimulating adenylyl cyclase but not 
for phospholipase Cβ. These observations suggest that cis-activation of LHR stimulates both 
adenylyl cyclase and phospholipase Cβ, whereas trans-activation of LHR is limited to adenylyl 
cyclase. Therefore, the modulation of the endodomain by the exodomain during trans-activation 
is likely limited. Our group showed that mutations at downstream of the N-terminal region, 
L103A, I105A, L179A, and L202A do not allow trans-activation (43). A simple explanation is that 
the location of non-binding mutations plays a role in trans-activation. The non-binding mutations 
in the N-terminal region are permissible for trans-activation, whereas the non-binding mutations 
downstream of N-terminal region are not. Interestingly, some amino acids residues in this non-
permissible region are involved in modulating the endodomain and the signal generation. S255 of 
LHR suppresses the endodomain (30) and G91 of LHR activates it (26). These residues are 
conserved in the FSH, LH, and TSH receptor. Furthermore, there is evidence that these regions 
make contacts with the endodomain (28, 36). Since the hormones also interact with the 
exodomain and endodomain, it is likely that the interactions among the hormone, exodomain, 
and the endodomain differ in trans-activation and cis-activation. The interactions appear to be 
more restricted in trans-activation. 
 
The absence of IP induction by LHR trans-activation provides a clue to our understanding of 
100-fold higher EC50 of IP production compared to cAMP production. Trans-activation provides 
a mechanism of hormone signal amplification at the receptor level as was demonstrated by 
cAMP rescuing, thus the LHR could achieve maximal cAMP induction at low hormone 
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concentrations, but this was not seen with IP signaling. The IP signaling pathway only seems to 
be mediated by cis-activation, which requires more hormones for phospholipase Cβ activation. 
 
Another possibility for the lack of IP induction by the trans-activation of the LHR might be due 
to low affinity of Gi2 to the LHR compared to that of Gs. It has not been determined how much 
Gs and Gi2 are endogenously expressed in HEK 293 cells. Future study including overexpression 
of Gi2 in HEK 293 cells with coexpression of two defective heterozygous LHRs will help to 
elucidate whether the lack of IP induction is due to more restriction of hormone-receptor contacts 
in trans-activation than in cAMP induction or to low affinities of Gi2 to the LHR.  
 
It has been an enigma as to how a hormone receptor can generate two or more signals, such as 
LHR being capable of activating two enzymes, adenylyl cyclase and phospholipase Cβ. 
Particularly, it is unclear whether one receptor molecule can generate only one signal or two 
distinct signals at a time. If the former is the case, cis- and trans-activation provide a mechanism 
for generation of two signals by one receptor. For example, a liganded LHR could cis-activate 
itself to stimulate phospholipase Cβ and trans-activate another LHR to stimulate adenylyl 
cyclase. This mechanism would allow one liganded receptor to generate multiple signals without 
a receptor simultaneously interacting with multiple G proteins. 
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Table 3.1     Surface expression of Flag-LHRs 
 
Cells were transfected with various Flag-LHR plasmids and assayed for 125I-monoclonal anti 
Flag-antibody binding in the presence of increasing concentrations of unlabeled antibody as 
described under "Materials and Methods." Specific antibody bindings were determined and 
compared with the specific binding of the Flag-LHRWT. 
 
 
125I-anti-Flag mAb 
Binding (%) 
LHRWT                   5 ± 3 
Flag-LHRWT               100 ± 9 
Flag-LHRC22A                 25 ± 3 
Flag-LHRI55A                 33 ± 5 
Flag-LHRI80A                 30 ± 5 
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Figure 3.1   Will there be trans-activation of LHR for inositol phosphate signaling? A. 
Domain structure of LHR showing the exodomain where the ligand binds and the endodomain 
where the hormone signal is generated. B. Cis- and trans-activation of monomeric LHRs. Trans-
activation of the LHR generates cAMP signaling. The ligand is shown in red. C. Hypothesis of 
trans-activation of a non-binding mutant LHR (LHR-hCG/+IP) by a mutant LHR that is capable of 
hormone binding but defective in signal generation (LHR+hCG/-IP) Normal parts are shown in gray 
and defective parts are shown in blue. D. Hypothesis of trans-activation of a mutant LHR (LHR-
hCG/+IP) by a chimera with a functional LHR exodomain linked to the non-functional CD 8 
transmembrane and cytoplasmic domain (ExoCD). Normal parts are shown in gray and defective 
parts are shown in blue. 
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Figure 3.2   Activity of mutant receptors. HEK 293 cells stably expressing wild-type or mutant 
LHRs were established by transfecting each with 12 µg of receptor plasmid followed by G-418 
selection. The cells were assayed for 125I-hCG binding in the presence of increasing 
concentrations of unlabeled hCG (A). In addition, the cells were treated with increasing 
concentrations of unlabeled hCG, and intracellular cAMP (B) and inositol phosphates including 
inositol mono- (IP1), bis- (IP2), and tris-phosphates (IP3) (C) were measured as described under 
"Materials and Methods." The experiments were performed in duplicate and repeated three to 
four time (n=6-8). The means and standard deviations are presented in the table (below panels A-
C). NS, not significant. 
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Figure 3.3   Induction of inositol phosphates from LHRWT. HEK 293 cells either stably or 
transiently expressing LHRWT were established. The cells were assayed for intracellular inositol 
phosphates (IP1, IP2, and IP3) induction in response to hCG as described in the legend for Figure 
3.2. 
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Figure 3.4   Coexpression of LHRK583R and LHR-hCG. 12 µg of LHRK583R plasmid was 
cotransfected into HEK 293 cells with 6 µg of various mutant LHR plasmid, respectively. The 
cells were assayed for hormone binding and cAMP and IP induction in response to hCG, as 
described in the legend for Figure 3.2. 
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Figure 3.5   Coexpression of ExoCD and LHR-hCG. 12 µg of ExoCD plasmid was 
cotransfected into HEK 293 cells with 6 µg of various mutant LHR plasmid, respectively. The 
cells were assayed for hormone binding and cAMP and IP induction in response to hCG, as 
described in the legend for Figure 3.2. 
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Figure 3.6   Coexpression of stable LHR and transient LHR. HEK 293 cells expressing stable 
LHR+hCG/-cAMP and transient LHR-hCG, or vice versa, were assayed for hormone binding and 
intracellular cAMP and IP induction in response to hCG, as described in the legend for Figure 
3.2. 
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Figure 3.7   Coexpression of stable ExoCD and stable LHR-hCG. 6 µg of ExoCD plasmid and 
6 µg of various LHR-hCG plasmid was transfected into HEK 293 cells followed by G-418 
selection. The cells were assayed for hormone binding and cAMP and IP induction in response to 
hCG, as described in the legend for Figure 3.2. 
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Figure 3.8   Coexpression of LHRK583R and TM4 LHR-hCG. 12 µg of LHRK583R plasmid was 
co-transfected with 6 µg of LHRP479A or LHRP479G plasmid in HEK 293 cells, respectively. The 
cells were assayed for hormone binding and cAMP and IP induction in response to hCG, as 
described in the legend for Figure 3.2. 
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Figure 3.9   Coexpression of LHRWT with LHR-hCG and LHR+hCG/-cAMP. LHRI80A with 
pcDNA3 vector and LHRI80A with LHRK583R plasmids were transiently transfected into HEK 293 
cells stably expressing LHRWT. The cells were assayed for IP induction in response to hCG, as 
described in the legend for Figure 3.2. 
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Chapter 4     Overlapping G Protein Binding Sites of the LHR 
 
Introduction 
 
Ligand/hormone binding to its cognate receptor leads to receptor activation and signal 
transduction. Receptors for LH, FSH, and TSH belong to the G protein-coupled receptor (GPCR) 
family and are unique in structure, possessing two halves of ~350 amino acids; the N-terminal 
extracellular hormone binding exodomain and the C-terminal half endodomain including three 
exoloops, seven transmembrane helices, and three cytoloops, responsible for signal generation 
(7). Hormone binding to the high affinity exodomain leads to conformational changes in the 
hormone/exodomain complex and  modulates hormone signals from endodomain of the receptor, 
especially through the exoloops (24). The LHR activates both adenylyl cyclase and 
phospholipase Cβ to induce cAMP and inositol phosphate, respectively (17, 77). Our group 
showed that certain amino acids in exoloops 2 and 3 of the LHR and FSHRs are critical for 
hormone binding and signal generation (33, 34, 45), and the exoloop 3 of the FSHR physically 
contacts with the exodomain (32, 46). Multiple hormonal signals of the LHR and FSHR are 
distinct and considered to be generated at the exoloops (32, 46). Gudermann’s group and 
Hunzicker-Dunn’s group showed the involvement of both Gs and Gi with the LHR in membranes 
of bovine corpus luteum and L cells (78) and in porcine ovarian follicular membranes (87), 
respectively. Gudermann’s group further identified that the LHR activates phospholipase C via 
preferential coupling to Gi2 (44). 
 
There are a small number of receptors that couple to G proteins for the activation of both 
adenylyl cyclase and phospholipase Cβ. These include receptors for the LH (17), FSH (88), TSH 
(89), GnRH (90), PACAP (91, 92), PTH (93), and calcitonin (94). Interestingly, all of these 
receptors belong to a subfamily of GPCRs which recognize peptide hormones as their ligands. 
An exception to this case is the P2Y11 receptor which has high affinity to the small nucleotide 
ATP. The P2Y11 receptor is, however, more homologous to G protein-coupled peptide hormone 
receptors than to receptors for structurally related small nucleotide ligands (95), and it also 
preferentially couples to phospholipase Cβ compared to adenylyl cyclase (96), whereas other 
peptide hormone receptors have preferential coupling to adenylyl cyclase. In addition to the G 
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protein-coupled peptide hormone receptor subfamily, histamine receptor (97) and α2A-adrenergic 
receptor (98) also activate both adenylyl cyclase and phospholipase Cβ. 
 
Usually amino acids in the exoloops affect differential ligand signaling (46, 99), but certain 
mutations in the transmembrane domain and cytoloop areas have been shown to affect multiple 
signaling of receptors. Tyr601 (TM5) of the TSH receptor (100, 101) and Ser232 (cytoloop 3) of 
the α2A-adrenergic receptor (98) serve as molecular switches to transduce cAMP and inositol 
phosphate signaling selectively. Due to the location of these mutations near the receptor-G 
protein coupling site, cytoloop 3, Tyr601 and Ser232 mutations are considered to affect structural 
requirements of the receptors for proper G protein-coupling. 
 
This dual and differential cAMP and inositol phosphate signaling of these G protein-coupled 
receptors requires sophisticated cellular machinery along with G proteins, such as Gs, Gi, and/or 
Gq, and effector molecules. For example, wild type H1 and H2 histamine receptors, when 
expressed in human breast epithelial cells, produced inositol phosphate but failed to produce 
cAMP, though both signaling pathways are functional in those cells (102). 
 
Studies using carboxyl terminal minigene peptides of G proteins indicate that different G 
proteins may have overlapping binding sites on the thrombin receptor (103) and the α1B- and 
α2A-adrenergic receptors (104), but it has not yet been elucidated with the LHR. We studied this 
dual G protein-coupling mechanism of the LHR using transient expressions of Gs, Gi, and their 
carboxyl terminal peptides with wild type and mutant LHRs. A constitutively activating TM6 
mutant LHR, LHRD578G, provides a valuable tool to study G protein interactions with the LHR 
due to its elevated cAMP level in the absence of hormone (105). The D578G mutation is the most 
common cause of male-limited precocious puberty (106).   
 
The data presented in this dissertation demonstrate that coexpression of the Gi2 carboxyl terminal 
region (Gi2CT) surprisingly enhanced cAMP induction from the mutant LHRD578G, whereas the 
Gi2CT inhibited cAMP induction from the wild type LHR. Coexpression of Gi2 whole molecule 
with LHRD578G completely inhibited elevated cAMP level of the LHRD578G in the absence of 
hormone to the basal level of LHRWT, suggesting its application to the development of future 
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therapeutics for the treatment of patients with Asp578 to Gly mutation. Coexpression of Gq or G12 
with the LHRD578G did not affect agonist-dependent cAMP induction. The data suggests that the 
LHR has overlapping binding sites for Gs and Gi2. 
 
Materials and Methods 
 
Mutagenesis and Functional Expression of Receptors and G proteins-- Mutant human LHRD578G 
cDNA was prepared in a pSELECT vector using the non-polymerase chain reaction-based 
Altered Sites Mutagenesis System (Promega), sequenced, and subcloned into pcDNA3 
(Invitrogen) as described previously (107). After subcloning into pcDNA3, the mutant cDNA 
was sequenced again. Human G proteins were purchased from Guthrie (Sayre, PA). The 
carboxyl terminal G protein peptides were constructed using PCR. cDNAs encoding amino acids 
288-380 (93 a.a.) of Gs (GsCT) and 280-355 (76 a.a.) of Gi2 (Gi2CT) were amplified from G 
protein cDNAs in pcDNA3.1 and subcloned into BamHI/XbaI sites of a pcDNA3 containing 
haemagglutinin epitope. 1:1 ratio of receptor (6 µg) and G protein plasmids (6 µg) were 
transfected into human embryonic kidney (HEK) 293 cells by the calcium phosphate method (64). 
Transiently transfected cells were assayed 60-72 h after transfection. All assays were carried out 
in duplicate and repeated three to four times (n=6-8). Means and standard deviations were 
calculated.  
 
cAMP assay procedure is same as described in the "Materials and Methods" of the Chapter 2. 
 
Results 
 
Competition of GsCT with endogenous Gs -- To investigate the interaction of G proteins and the 
LHR, first we transfected 6 µg of 93-amino acid GsCT plasmid with 6 µg of the wild type and 
mutant LHR plasmids, respectively, in HEK 293 cells (Fig. 1). Our previous study on transient 
expressions of the LHR in HEK 293 cells shows that 5,000-7,000 receptor/cell are expressed 
with transfection of 6 µg of the LHR cDNA plasmid (42), which is consistent with LHR numbers 
in physiological conditions (15, 16). Coexpression of GsCT competitively inhibited cAMP 
induction from both LHRWT and LHRD578G, but this inhibition of cAMP by GsCT was not 
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complete (Figure 4.1). This data suggest that the 93-amino acid GsCT competes for binding to 
the LHR with endogenous Gs molecules. 
 
Enhancement of cAMP induction by Gi2CT -- Next, we transfected 76-amino acid Gi2CT plasmid 
with LHRWT and LHRD578G, respectively, in HEK 293 cells (Figure 4.1). Coexpression of Gi2CT 
inhibited cAMP induction from LHRWT, but when Gi2CT was coexpressed with LHRD578G, it 
surprisingly increased already elevated cAMP level two fold and, plus enhanced  hormone-
induced cAMP induction. These data suggest that upon Gi2CT binding to the cytoloop 3 and 
other G protein-coupling sites on the LHR, there were structural changes, either allosterically or 
non-allosterically, which facilitated Gs-coupling to the LHRD578G. The enhancement of cAMP 
induction by coexpression of 76-amino acid Gi2CT with LHRD578G also suggests that the LHR 
has different or overlapping binding sites for Gs and Gi2.  
 
Gs increases basal cAMP level -- Although the carboxyl terminal region of Gs and Gi2 seems to 
have overlapping binding sites on the LHR, it is unclear whether Gs or Gi2 whole molecules can 
compete for binding to the same LHR. First, Gs was coexpressed with LHRWT and LHRD578G, 
respectively, in HEK 293 cells (Figure 4.2). Gs facilitated basal cAMP level from both LHRWT 
and LHRD578G, but as wild type and mutant LHRs are activated by hormone, both receptors 
restored their normal cAMP induction curve, and the effect of Gs was minimal.  
 
Inverse Agonism  of Gi2 on LHRD578G -- We coexpressed the Gi2 whole molecule with LHRWT 
and LHRD578G, respectively (Figure 4.2). When Gi2 was coexpressed with LHRD578G, it 
completely inhibited its elevated basal and hormone-induced cAMP level down to the basal level 
of LHRWT. As was suggested with enhancement of cAMP induction with Gi2CT, these data 
suggest that LHRD578G has more exposed G protein binding sites than LHRWT, thus promoting 
Gi2 binding. Also, Gi2 inhibited hormone-induced cAMP induction from LHRWT but did not 
affect the basal cAMP level of LHRWT, suggesting that LHRWT keeps its basal cAMP level low. 
 
We also transiently expressed Gs and Gi2, respectively, in HEK 293 cells stably expressing wild 
type LHRs (> 100,000 receptors/cell). The effect of transient expression of Gs or Gi2 was small 
compared to transient expression of both receptor and G proteins (data not shown). This 
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indicates that there is a stoichiometric relationship of interactions between the LHR and G 
proteins. 
 
Discussion 
 
The Asp578Gly mutation is the most common cause of male-limited precocious puberty. This 
mutant LHR shows 4-7 fold increased cAMP basal level in the absence of hormone, but the 
maximal cAMP induction reaches 70-80% of wild type LHR. Substitutions of Glu, Tyr, and His 
for Asp578 were also found in patients. Inhibition of cAMP induction by coexpression of Gi2 
suggests that Gi2 can work as an inverse agonist for the constitutively activating Asp578Gly 
mutant LHR. In addition to the frequent mutations of Asp578 in the LHR, an activating mutation 
of the FSHR bearing Asp567Gly mutation (TM6) was found in a hypophysectomized man (108). 
This activating FSHR mutation has so far been the only case of activating mutation among 
FSHR mutations, and like the activating mutations of the LHR with the corresponding amino 
acid Asp578Gly, it had elevated cAMP level when transfected into COS-7 cells in the absence of 
hormone. The findings from this study may be helpful to the development of future therapeutics 
for the treatment of patients with activating mutations of the LH or FSHR. 
 
Studies using the carboxyl terminal minigene peptides of G proteins suggest that G proteins may 
have overlapping binding sites on the receptor. Hamm’s group showed that 13-amino acid 
minigene peptides of different G protein carboxyl termini specifically inhibited the thrombin 
receptor-G protein interactions (103). Luttrell’s group showed that an 83-amino acid peptide of 
Gs carboxyl terminal region selectively inhibited Gs coupling without affecting Gi or Gq-coupled 
phosphoinositide hydrolysis from the α1B- and α2A-adrenergic receptors (104). The use of this 
relatively large 83-amino acid peptide suggests that Gs binding sites on the receptor may be 
different or not too much overlapped with Gi or Gq binding sites (104). This observation is also 
consistent with our data that a 73-amino acid Gi2CT facilitates Gs binding to the LHR enhancing 
cAMP induction. Berlot showed that coexpression of a dominant-negative Gs with the calcitonin 
receptor inhibited both cAMP and inositol phosphate signaling, suggesting Gs and Gq compete 
for binding to the same receptor (109). 
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Trans-activation of the LHRs lead to the activation of adenylyl cyclase to induce cAMP, but 
failed to activate phospholipase Cβ to induce inositol phosphate. This raises an intriguing 
possibility that a liganded LHR could cis-activate phospholipase Cβ and trans-activate adenylyl 
cyclase simultaneously. Trans-activation of the LHR and the results on overlapping G protein 
binding sites on the LHR from this study suggest a mechanism of simultaneous multiple G 
protein activations, with activation one G protein at a time from a single LHR. 
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Table 4.1     Effect of Gs, Gi2, and their carboxyl terminal peptides on the cAMP induction 
of LHRWT and LHRD578G 
 
 
 cAMP induction 
 EC50 (nM) 
Basal 
(fmol/1000 cells) 
Max 
(fmol/1000 cells) 
  LHRWT + pcDNA3 0.21 ± 0.02        10.3 ± 1.1      157.2 ± 0.2 
  LHRWT + GsCT 0.32 ± 0.06          8.6 ± 0.4        79.6 ± 1.1 
  LHRWT + Gi2CT 0.72 ± 0.36        26.3 ± 2.8        60.5 ± 0.4 
  LHRWT + Gs 0.30 ± 0.24        42.7 ± 2.9      156.5 ± 12.9 
  LHRWT + Gi2 0.68 ± 0.22        10.9 ± 1.5        79.3 ± 16.8 
  LHRD578G + pcDNA3 0.48 ± 0.01        46.4 ± 6.6      122.5 ± 1.2 
  LHRD578G + GsCT 0.38 ± 0.18        33.5 ± 1.0        65.1 ± 2.5 
  LHRD578G + Gi2CT 0.88 ± 0.13        86.0 ± 1.3      167.3 ± 11.8 
  LHRD578G + Gs 0.42 ± 0.08        79.0 ± 7.3      125.0 ± 0.1 
  LHRD578G + Gi2 NS          7.2 ± 0.6          7.9 ± 0.8 
          (NS: Not Significant)
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Figure 4.1   Effect of GsCT and Gi2CT on cAMP induction of LHRWT and LHRD578G.  6 µg 
of LHR plasmid and 6 µg of GsCT or Gi2CT minigene plasmid were transfected into HEK 293 
cells, respectively. 60-72 hours after transfection, cells were assayed for cAMP induction.  
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Figure 4.2   Effect of Gs and Gi2 on cAMP induction of LHRWT and LHRD578G.  6 µg of LHR 
plasmid and 6 µg of Gs or Gi2 plasmid were transfected into HEK 293 cells, respectively. 60-72 
hours after transfection, cells were assayed for cAMP induction.  
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